All News

Oslo-based anticancer company Algeta has closed a series A financing round totaling €23 million.

Michael Kenward's roundup of new studies, reports and tools for the business of science

Mary Lisbeth D'Amico's first fortnightly funding column reveals how coming out on top in a start-up talent show does not guarantee funding.

Take care: not all spin-outs end in fame and glory. The path from academia to industry is strewn with pitfalls…

Scientists love to complicate things; and if you're not in the same field, or – worse – are in business or investment, then it's easy to get lost. Enter the Science|Business Quick Guides to some of the hottest fields of science and technology…

One of Europe’s biggest research organisations, Fraunhofer Gesellschaft in Germany, is pushing to close its first venture fund to finance spin-off companies from the institute.

Europe looks increasingly likely to follow America’s lead and require drug companies to test their products in children. But Europe's pharma lack the resources to carry out drug trials in children — so industry and patients will have to rely on the skills developed in academic centres.

IBM’s savvy move to share 500 patents may spark innovation in computer software and in how companies handle IP.

Technology from one of France’s Grandes Écoles is going towards developing an easy-to-program home robot – with a common touch

Acquisition gives Roche access to antibody-boosting technology - and possible anti-cancer treatments in the pipeline

How a Swiss university spin-off got to exit in six years - Interview with Joël Jean-Mairet, Chief Executive Officer and Joint Founder, GlycArt.

By mixing academic research with commercial ventures, Sir Richard Friend has returned to the scientific traditions of Faraday and Kelvin. He has also created a new role model for the modern scientist.